Consolidated Statements Of Operations (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2012	Mar. 31, 2011	Mar. 31, 2012	Mar. 31, 2011
Consolidated Statements Of Operations [Abstract]
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	861,571	1,512,331	5,649,626	5,391,997
Research and development (including stock-based compensation (Note 8))	34,810	478,804	133,304	579,761
Total operating expenses	896,381	1,991,135	5,782,930	5,971,758
Loss from operations	(896,381)	(1,991,135)	(5,782,930)	(5,971,758)
Other expense (income):
Interest expense	35,431	5,202	49,861	14,324
Interest income	(331)	(1,145)	(2,033)	(4,140)
Total Nonoperating Income/Expense	35,100	4,057	47,828	10,184
Net loss	(931,481)	(1,995,192)	(5,830,758)	(5,981,942)
Net loss attributable to the noncontrolling interest	1,360	1,335	15,634	4,428
Net loss attributable to Bion	(930,121)	(1,993,857)	(5,815,124)	(5,977,514)
Conversion inducement (Note 8)			(755,258)
Dividends on preferred stock	(1,875)	(150,800)	(153,300)	(405,574)
Net loss applicable to Bion's common stockholders	$ (931,996)	$ (2,144,657)	$ (6,723,682)	$ (6,383,088)
Net loss applicable to Bion's common stockholders per basic and diluted common share	$ (0.06)	$ (0.17)	$ (0.44)	$ (0.52)
Weighted-average number of common shares outstanding:
Basic and diluted:	16,145,128	12,410,074	15,134,477	12,221,712